{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:33:51Z","timestamp":1786653231163,"version":"build-2736575974"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Cancer"],"published-print":{"date-parts":[[2014]]},"DOI":"10.4103\/0019-509x.175371","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T06:37:37Z","timestamp":1454481457000},"page":"531","source":"Crossref","is-referenced-by-count":9,"title":["Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India"],"prefix":"10.4103","volume":"51","author":[{"given":"VH","family":"Veldore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MR","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SA","family":"Prabhudesai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Tejaswi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kakara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Pattanayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BN","family":"Tejaswini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hazarika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gangoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SM","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RB","family":"Diwakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CT","family":"Satheesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HP","family":"Shashidhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KS","family":"Gopinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BS","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-509X.175371-1","first-page":"E359","volume-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"key-10.4103\/0019-509X.175371-2","first-page":"871","volume-title":"Increasing incidence of colorectal cancer in Asia: Implications for screening","author":"Sung","year":"2005","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0019-509X.175371-3","first-page":"69","volume-title":"Global cancer statistics","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0019-509X.175371-4","first-page":"004","volume-title":"Interesting trends in incidence and mortality rates of colorectal cancer in the United States of America","author":"Mateka","year":"2013","journal-title":"J Gastrointest Dig Syst"},{"key":"key-10.4103\/0019-509X.175371-5","unstructured":"National Cancer Registry Programme. Population based cancer registries 2004-2005. New Delhi: Indian Council of Medical Research; 2008. [www.ncrpindia.org\/Reports\/PBCR_Rpt_2004_05.aspx]."},{"key":"key-10.4103\/0019-509X.175371-6","first-page":"759","volume-title":"A genetic model for colorectal tumorigenesis","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"key-10.4103\/0019-509X.175371-7","first-page":"1348","volume-title":"Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs","author":"Ciardiello","year":"2003","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0019-509X.175371-8","first-page":"147","volume-title":"Understanding Ras: 'It ain't over 'til it's over'","author":"Shields","year":"2000","journal-title":"Trends Cell Biol"},{"key":"key-10.4103\/0019-509X.175371-9","first-page":"499","volume-title":"Tyrosine kinase inhibitors: From rational design to clinical trials","author":"Traxler","year":"2001","journal-title":"Med Res Rev"},{"key":"key-10.4103\/0019-509X.175371-10","first-page":"3992","volume-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","author":"Li\u00e8vre","year":"2006","journal-title":"Cancer Res"},{"key":"key-10.4103\/0019-509X.175371-11","first-page":"1626","volume-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.175371-12","first-page":"1166","volume-title":"Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy","author":"Di","year":"2007","journal-title":"Br J Cancer"},{"key":"key-10.4103\/0019-509X.175371-13","first-page":"675","volume-title":"Kirsten ras mutations in patients with colorectal cancer: The multicenter \"RASCAL\" study","author":"Andreyev","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/0019-509X.175371-14","unstructured":"Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, et al. Randomized phase III study of irinotecan and 5-FU\/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. In: Program and Abstracts of the 43rd American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, IL. Abstract 4000."},{"key":"key-10.4103\/0019-509X.175371-15","unstructured":"Van Cutsem E, Lang I, D'haens G, Moiseyenko, Zaluski J, Folprecht G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. In: Program and Abstracts of the 44rd American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, IL. Abstract 2."},{"key":"key-10.4103\/0019-509X.175371-16","unstructured":"Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, et al. KRAS status and efficacy of first-time treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. In: Program and abstracts of the 44rd American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, IL. Abstract 4000."},{"key":"key-10.4103\/0019-509X.175371-17","doi-asserted-by":"crossref","unstructured":"Punt CJ, Tol J, Rodenburg CJ, Cats A, Creemers G, SchramaJG. et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). In: Program and abstracts of the 44rd American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, IL. Abstract LBA4011.","DOI":"10.1200\/jco.2008.26.15_suppl.lba4011"},{"key":"key-10.4103\/0019-509X.175371-18","unstructured":"Hecht JR, Mitchell E, Chidiac T, Carroll Scroggin, Christopher Hagenstad, David Spigel, et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)\/bevacizumab (bev) +\/-panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized controlled trial (PACCE). In: Program and abstracts of the 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 273."},{"key":"key-10.4103\/0019-509X.175371-19","first-page":"1130","volume-title":"KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: Practical application of patient selection","author":"Jimeno","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.175371-20","first-page":"2091","volume-title":"American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy","author":"Allegra","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.175371-21","unstructured":"Guidelines Established for KRAS Mutation Testing of Colorectal Carcinoma Samples: Practice Guidelines Established for KRAS Mutation Testing in Colorectal Cancers: National Comprehensive Cancer Network Guidelines on Colon and Rectal Cancers. PA, USA: NCCN; 2008."},{"key":"key-10.4103\/0019-509X.175371-22","first-page":"4682","volume-title":"Ras oncogenes in human cancer: A review","author":"Bos","year":"1989","journal-title":"Cancer Res"},{"key":"key-10.4103\/0019-509X.175371-23","first-page":"508","volume-title":"KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.Ann Oncol","author":"De","year":"2008","journal-title":""},{"key":"key-10.4103\/0019-509X.175371-24","first-page":"518","volume-title":"Ki-ras mutations and prognosis in colorectal cancer","author":"Kressner","year":"1998","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0019-509X.175371-25","first-page":"493","volume-title":"KRAS mutations: An old oncogene becomes a new predictive biomarker","author":"Riely","year":"2008","journal-title":"J Mol Diagn"},{"key":"key-10.4103\/0019-509X.175371-26","first-page":"367","volume-title":"K-ras mutation in colorectal cancer: Relations to patient age, sex and tumour location","author":"Breivik","year":"1994","journal-title":"Br J Cancer"},{"key":"key-10.4103\/0019-509X.175371-27","first-page":"809","volume-title":"Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients","author":"Shen","year":"2011","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/0019-509X.175371-28","first-page":"146","volume-title":"Relationship between expression of ras p21 oncoprotein and mutation status of the K-ras gene in sporadic colorectal cancer patients in Tunisia","author":"Sammoud","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"key-10.4103\/0019-509X.175371-29","first-page":"55","volume-title":"Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan","author":"Wu","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"key-10.4103\/0019-509X.175371-30","first-page":"97","volume-title":"Evaluation of K-RAS gene in colorectal cancer","author":"Okulczyk","year":"2003","journal-title":"Folia Histochem Cytobiol"},{"key":"key-10.4103\/0019-509X.175371-31","first-page":"664","volume-title":"Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors","author":"Breivik","year":"1997","journal-title":"Int J Cancer"},{"key":"key-10.4103\/0019-509X.175371-32","first-page":"191","volume-title":"K-ras mutation in colorectal carcinomas from singapore","author":"Phang","year":"1995","journal-title":"Int J Oncol"},{"key":"key-10.4103\/0019-509X.175371-33","first-page":"1020","volume-title":"KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients","author":"Knijn","year":"2011","journal-title":"Br J Cancer"},{"key":"key-10.4103\/0019-509X.175371-34","first-page":"13","volume-title":"Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials","author":"Sorich","year":"2015","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.175371-35","first-page":"899","volume-title":"How to select the optimal treatment for first line metastatic colorectal cancer","author":"Stein","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/0019-509X.175371-36","first-page":"6935","volume-title":"Associations between dietary intake and Ki-ras mutations in colon tumors: A population-based study","author":"Slattery","year":"2000","journal-title":"Cancer Res"},{"key":"key-10.4103\/0019-509X.175371-37","unstructured":"DxS\/THERASCREEN\u00ae Package Insert. UK: DsX, Manchester; 2009. https:\/\/www.qiagen.com\/resources\/download.aspx?id=0457593b"},{"key":"key-10.4103\/0019-509X.175371-38","doi-asserted-by":"crossref","unstructured":"(A) Ries L AG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975\u20132005. Bethesda, MD: 2008. (B) Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004 1;101 (1):3-27. (C) http:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html.","DOI":"10.1002\/cncr.20288"},{"key":"key-10.4103\/0019-509X.175371-39","first-page":"292","volume-title":"A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: A morphology-based approach in colorectal carcinoma","author":"Angulo","year":"2010","journal-title":"J Mol Diagn"},{"key":"key-10.4103\/0019-509X.175371-40","first-page":"543","volume-title":"A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting","author":"Whitehall","year":"2009","journal-title":"J Mol Diagn"},{"key":"key-10.4103\/0019-509X.175371-41","first-page":"316","volume-title":"Screening for EGFR mutations in lung cancer, a report from India","author":"Sahoo","year":"2011","journal-title":"Lung Cancer"},{"key":"key-10.4103\/0019-509X.175371-42","first-page":"163","volume-title":"The frequency and spectrum of K-ras mutations among Iraqi patients with sporadic colorectal carcinoma","author":"Al-Allawi","year":"2012","journal-title":"Indian J Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0019-509X","issn-type":"print"},{"key":"key-10.4103\/0019-509X.175371-43","first-page":"1193","volume-title":"Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study","author":"Samowitz","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key-10.4103\/0019-509X.175371-44","first-page":"491","volume-title":"C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas","author":"Elnatan","year":"1996","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0019-509X.175371-45","first-page":"1443","volume-title":"Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics","author":"Einspahr","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key-10.4103\/0019-509X.175371-46","unstructured":"Baskin Y, Dagdeviren YK, Calibasi G, Canda AE, Sarioglu S, Ellidokuz H, Oztop I. KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas. J Gastrointest Oncol. 2014 Aug;5(4):265-9"},{"key":"key-10.4103\/0019-509X.175371-47","first-page":"8886","volume-title":"Intestinal microbiota in pathophysiology and management of irritable bowel syndrome","author":"Lee","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/0019-509X.175371-48","unstructured":"Faulkner NE, Da Silva MM, Heim RA, Horten BC, Rohlfs EM, Rosenblum LS, et al. KRAS Mutation Analyses of >16,500 Colorectal Carcinomas. Presented at: ASCO\u2013NCI\u2013EORTC Annual Meeting: Molecular Markers in Cancer. Brussels, Belgium, 18-20 October, 2010."},{"key":"key-10.4103\/0019-509X.175371-49","unstructured":"Parkin DM, Whelan SL, Ferlay L, Young RJ. Cancer Incidence in Five Continents (IARC Sci. Publ. No. 143) Series. Vol. 143. Lyon: International Agency for Research on Cancer; 1997. p. 566-7."},{"key":"key-10.4103\/0019-509X.175371-50","first-page":"261","volume-title":"KRAS mutation testing of metastatic colorectal cancer in Australia: Where are we at?","author":"Scott","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"key":"key-10.4103\/0019-509X.175371-51","first-page":"1042","volume-title":"Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer","author":"Nakanishi","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"key-10.4103\/0019-509X.175371-52","first-page":"2378","volume-title":"Prognostic value of KRAS mutations in stage III colon cancer: Post hoc analysis of the PETACC8 phase III trial dataset","author":"Blons","year":"2014","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.175371-53","first-page":"1757","volume-title":"KRAS-mutation status in relation to colorectal cancer survival: The joint impact of correlated tumour markers","author":"Phipps","year":"2013","journal-title":"Br J Cancer"},{"key":"key-10.4103\/0019-509X.175371-54","first-page":"e47345","volume-title":"Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: A TTD group cooperative study","author":"D\u00edaz-Rubio","year":"2012","journal-title":"PLoS One"},{"key":"key-10.4103\/0019-509X.175371-55","first-page":"703","volume-title":"K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study","author":"Brink","year":"2003","journal-title":"Carcinogenesis"},{"key":"key-10.4103\/0019-509X.175371-56","first-page":"584","volume-title":"KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese","author":"Zhu","year":"2012","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"key-10.4103\/0019-509X.175371-57","first-page":"124","volume-title":"Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: Determination of frequency, distribution pattern in Indian colorectal carcinoma","author":"Bisht","year":"2014","journal-title":"Med Oncol"},{"key":"key-10.4103\/0019-509X.175371-58","first-page":"219","volume-title":"Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: A report","author":"Sameer","year":"2009","journal-title":"Indian J Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0019-509X","issn-type":"print"},{"key":"key-10.4103\/0019-509X.175371-59","first-page":"e60142","volume-title":"Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: Indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population","author":"Sinha","year":"2013","journal-title":"PLoS One"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:33:55Z","timestamp":1786649635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0019-509X.175371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"alternative-id":["175371"],"URL":"https:\/\/doi.org\/10.4103\/0019-509x.175371","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}